Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1997-10-16
pubmed:abstractText
Episcleral plaque therapy (EPT) with sealed 125I sources is widely used in the treatment of choroidal melanoma. In EPT, as elsewhere in radiotherapy, concern for normal tissue tolerance has frequently been a dose-limiting factor. The concept of conformal therapy, which seeks to improve dose homogeneity within the tumor and greatly reduce the dose to uninvolved structures may provide a solution to this problem. Radioactive sources are typically distributed uniformly over the surface of an episcleral plaque and are sometimes offset slightly from the scleral surface to reduce the dose to the sclera relative to the apex and prescribed therapeutic margin at the tumor base. Nevertheless, it is not uncommon for scleral dose to exceed the dose to the apex of intermediate to tall tumors by a factor of 4 or more. The availability of low-energy sealed sources such as 125I prompted the development of gold-backed plaques to shield noninvolved periocular tissues. The concept of shielding can be extended to include collimation of individual sources. The potential advantages of individual source collimation include reduced scleral dose, more homogeneous tumor dose, and superior shielding of adjacent normal structures such as the fovea as compared to previous plaque designs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0360-3016
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
505-19
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Conformal episcleral plaque therapy.
pubmed:affiliation
Department of Radiation Oncology, University of Southern California School of Medicine, Los Angeles 90033, USA.
pubmed:publicationType
Journal Article